Rationale and design of the multicentric, double-blind, double-placebo, randomized trial APrepitant versus HYdroxyzine in association with cytoreductive treatments for patients with myeloproliferative neoplasia suffering from Persistent Aquagenic Pruritus. Trial acronym: APHYPAP

Trials

A. Gasse¹  L. Le Roux¹  J. C. Ianotto²  C. Le Gall-Ianotto³  L. Misery³  A. Fiedler⁴  D. Carlhant-Kowalski⁵  R. Verdet⁶  E. Nowak⁶  P. Marcorelles⁷ 

[1] Clinical investigation center, CIC, Inserm 1412, University Hospital of Brest, 29200, Brest, France;Department of Clinical Hematology, University Hospital of Brest, Brest, France;France Intergroup of Myeloproliferative neoplasms (FIM), Brest, France;Department of Dermatology, University Hospital of Brest, Brest, France;Univ Brest, LIEN, Brest, France;Department of Pharmacy, University Hospital of Brest, Brest, France;PPRIGO (Production Pharmaceutique pour la Recherche Institutionnelle du Grand Ouest), Brest coordinator, Brest, France;Pharmacovigilance Unit of Research and Innovation Department, University Hospital of Brest, Brest, France;Research and Innovation Department, University Hospital of Brest, Brest, France;Univ Brest, LIEN, Brest, France;Brest Biological Resources Center BB-0033-00037, University Hospital of Brest, Brest, France;Department of Pathology, University Hospital of Brest, Brest, France;

关键词: Aquagenic pruritus;    Myeloproliferative neoplasms;    Randomized controlled trial;    Aprepitant;    Hydroxyzine;   

DOI  :  10.1186/s13063-021-05864-8

来源: Springer

【 摘 要 】

BackgroundAquagenic pruritus (AP), an intense sensation of scratching induced after water contact, is the most troublesome aspect of BCR-ABL1-negative myeloproliferative neoplasms (MPNs). Mostly described in polycythemia vera (PV, ~ 40%), it is also present in essential thrombocythemia (ET) and primary myelofibrosis (PMF) (10%). Even if this symptom can decrease or disappear under cytoreductive treatments, 30% of treated MPN patients still persist with a real impact on the quality of life (QoL). Because its pathophysiology is poorly understood, efficient symptomatic treatments of AP are missing. The neuropeptide substance P (SP) plays a crucial role in the induction of pruritus. Several studies showed the efficacy of aprepitant, an antagonist of SP receptor (NK-1R), in the treatment of chronic pruritus but never evaluated in AP. The objectives of APHYPAP are twofold: a clinical aim with the evaluation of the efficacy of two drugs in the treatment of a persistent AP for MPN patients and a biological aim to find clues to elucidate AP pathophysiology.Methods/designA multicentric, double-blind, double-placebo, randomized study will include 80 patients with MPN (PV or ET or PMF) treated since at least 6 months for their hemopathy but suffering from a persistent AP (VAS intensity ≥6/10). Patients will be randomized between aprepitant (80 mg daily) + placebo to match to hydroxyzine OR hydroxyzine (25 mg daily) + placebo to match to aprepitant for 14 days. At D0, baseline information will be collected and drugs dispense. Outcome measures will be assessed at D15, D30, D45, and D60. The primary study endpoint will be the reduction of pruritus intensity below (or equal) at 3/10 on VAS at D15. Secondary outcome measures will include the number of patients with a reduction or cessation of AP at D15 or D60; evaluation of QoL and AP characteristics at D0, D15, D30, D45, and D60 with MPN-SAF and AP questionnaires, respectively; modification of plasmatic concentrations of cytokines and neuropeptides at D0, D15, D30, and D60; and modification of epidermal innervation density and pruriceptor expression at D0 and D15.DiscussionThe APHYPAP trial will examine the efficacy of aprepitant vs hydroxyzine (reference treatment for AP) to treat persistent AP in MPN patients. The primary objective is to demonstrate the superiority of aprepitant vs hydroxyzine to treat persistent AP of MPN patients. The treatment received will be considered efficient if the AP intensity will be reduced at 3/10 or below on VAS after 14 days of treatment. The results of this study may provide a new treatment option for this troublesome symptom and also give us more insights in the pathophysiology understanding of AP.Trial registrationAPHYPAP. NCT03808805, first posted: January 18, 2019; last update posted: June 10, 2021. EudraCT 2018-090426-66

【 授权许可】

CC BY